Furthermore, as the activation of the MAPK signalling pathway plays an important role in GBM response to chemotherapy, we used the potent and selective non-ATP-competitive MEK1 inhibitor PD98059 (preclinical studies). The gene discussed is MAP2K1; the disease is glioblastoma.